Scholarlink

Background <p>Liposarcoma (LS) is the second most common histological subtype of soft tissue sarcoma, accounting for approximately 7% of all soft tissue sarcomas, among which retroperitoneal liposarcoma (RPLS) is not a rare clinical entity. While RPLS involving the kidney and requiring combined urological management is relatively uncommon with limited clinical reports, it is often asymptomatic in the early stage, with clinical symptoms appearing only when the tumor compresses adjacent organs. Surgical resection is the cornerstone of treatment.</p> Case presentation <p>A 54-year-old female was diagnosed with a well-differentiated giant retroperitoneal RPLS (250&#xa0;mm × 92&#xa0;mm) compressing the right kidney via contrast-enhanced MRI. After strict multidisciplinary evaluation in accordance with the 2024 NCCN Guidelines for Soft Tissue Sarcoma, preoperative core needle biopsy was not performed, and the retroperitoneal approach was selected for surgical intervention. On August 6, 2024, Da Vinci Xi Surgical System robot-assisted retroperitoneal tumor resection combined with right nephrectomy and retroperitoneal lymph node dissection was successfully completed via the retroperitoneal approach. Postoperative pathology and immunohistochemistry (MDM2 (+), S-100 (+), etc.) confirmed the diagnosis. The patient recovered uneventfully and was discharged on postoperative day 6 with individualized adjuvant targeted therapy. Follow-up CT scans at 3 months, 6 months, and 1 year postoperatively showed no tumor recurrence, and laboratory examinations such as serum creatinine were normal. This case preliminarily confirms the feasibility and safety of robot-assisted retroperitoneal approach for strictly selected giant RPLS (&gt; 20&#xa0;cm) confined to the retroperitoneal space, and provides a standardized urological management reference for similar cases.</p> Discussion <p>Most existing robot-assisted retroperitoneal liposarcoma (RPLS) surgeries are performed via the transabdominal approach, and the reported cases of retroperitoneal approach are limited to moderately sized tumors (diameter &lt; 10&#xa0;cm). This case demonstrates the feasibility and safety of robot-assisted retroperitoneal approach for giant RPLS (&gt; 20&#xa0;cm) strictly confined to the retroperitoneal space, expands the application scope of this approach, and provides a standardized urological management strategy for RPLS compressing the kidney for clinical reference.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Robot-assisted nephrectomy for retroperitoneal liposarcoma compressing the kidney: a case report with urological management perspective

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Hao Shen,
  • Yuyong Wang,
  • Zhanwen Dong,
  • Jieting Wu

摘要

Background

Liposarcoma (LS) is the second most common histological subtype of soft tissue sarcoma, accounting for approximately 7% of all soft tissue sarcomas, among which retroperitoneal liposarcoma (RPLS) is not a rare clinical entity. While RPLS involving the kidney and requiring combined urological management is relatively uncommon with limited clinical reports, it is often asymptomatic in the early stage, with clinical symptoms appearing only when the tumor compresses adjacent organs. Surgical resection is the cornerstone of treatment.

Case presentation

A 54-year-old female was diagnosed with a well-differentiated giant retroperitoneal RPLS (250 mm × 92 mm) compressing the right kidney via contrast-enhanced MRI. After strict multidisciplinary evaluation in accordance with the 2024 NCCN Guidelines for Soft Tissue Sarcoma, preoperative core needle biopsy was not performed, and the retroperitoneal approach was selected for surgical intervention. On August 6, 2024, Da Vinci Xi Surgical System robot-assisted retroperitoneal tumor resection combined with right nephrectomy and retroperitoneal lymph node dissection was successfully completed via the retroperitoneal approach. Postoperative pathology and immunohistochemistry (MDM2 (+), S-100 (+), etc.) confirmed the diagnosis. The patient recovered uneventfully and was discharged on postoperative day 6 with individualized adjuvant targeted therapy. Follow-up CT scans at 3 months, 6 months, and 1 year postoperatively showed no tumor recurrence, and laboratory examinations such as serum creatinine were normal. This case preliminarily confirms the feasibility and safety of robot-assisted retroperitoneal approach for strictly selected giant RPLS (> 20 cm) confined to the retroperitoneal space, and provides a standardized urological management reference for similar cases.

Discussion

Most existing robot-assisted retroperitoneal liposarcoma (RPLS) surgeries are performed via the transabdominal approach, and the reported cases of retroperitoneal approach are limited to moderately sized tumors (diameter < 10 cm). This case demonstrates the feasibility and safety of robot-assisted retroperitoneal approach for giant RPLS (> 20 cm) strictly confined to the retroperitoneal space, expands the application scope of this approach, and provides a standardized urological management strategy for RPLS compressing the kidney for clinical reference.